These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10918271)

  • 1. Treatment of myasthenia gravis with mycophenolate mofetil: a case report.
    Meriggioli MN; Rowin J
    Muscle Nerve; 2000 Aug; 23(8):1287-9. PubMed ID: 10918271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil in the therapy of severe myasthenia gravis.
    Schneider C; Gold R; Reiners K; Toyka KV
    Eur Neurol; 2001; 46(2):79-82. PubMed ID: 11528156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil - as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience.
    Prakash KM; Ratnagopal P; Puvanendran K; Lo YL
    J Clin Neurosci; 2007 Mar; 14(3):278-81. PubMed ID: 16597503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis.
    Mowzoon N; Sussman A; Bradley WG
    J Neurol Sci; 2001 Apr; 185(2):119-22. PubMed ID: 11311292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity.
    Lim AK; Donnan G; Chambers B; Ierino FL
    Intern Med J; 2007 Jan; 37(1):55-9. PubMed ID: 17199845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study.
    Ciafaloni E; Massey JM; Tucker-Lipscomb B; Sanders DB
    Neurology; 2001 Jan; 56(1):97-9. PubMed ID: 11148243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The muddle of mycophenolate mofetil in myasthenia.
    Benatar M; Rowland LP
    Neurology; 2008 Aug; 71(6):390-1. PubMed ID: 18678821
    [No Abstract]   [Full Text] [Related]  

  • 8. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis.
    Muscle Study Group
    Neurology; 2008 Aug; 71(6):394-9. PubMed ID: 18434639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study.
    Narayanaswami P; Sanders DB; Thomas L; Thibault D; Blevins J; Desai R; Krueger A; Bibeau K; Liu B; Guptill JT;
    Lancet Neurol; 2024 Mar; 23(3):267-276. PubMed ID: 38365379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs.
    Abelson AL; Shelton GD; Whelan MF; Cornejo L; Shaw S; O'Toole TE
    J Vet Emerg Crit Care (San Antonio); 2009 Aug; 19(4):369-74. PubMed ID: 25164637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil.
    Hauser RA; Malek AR; Rosen R
    Neurology; 1998 Sep; 51(3):912-3. PubMed ID: 9748061
    [No Abstract]   [Full Text] [Related]  

  • 12. Lessons from two trials of mycophenolate mofetil in myasthenia gravis.
    Sanders DB; Siddiqi ZA
    Ann N Y Acad Sci; 2008; 1132():249-53. PubMed ID: 18567876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.
    Meriggioli MN; Ciafaloni E; Al-Hayk KA; Rowin J; Tucker-Lipscomb B; Massey JM; Sanders DB
    Neurology; 2003 Nov; 61(10):1438-40. PubMed ID: 14638974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive agents for myasthenia gravis.
    Hart IK; Sathasivam S; Sharshar T
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005224. PubMed ID: 17943844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.
    Chaudhry V; Cornblath DR; Griffin JW; O'Brien R; Drachman DB
    Neurology; 2001 Jan; 56(1):94-6. PubMed ID: 11148242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis.
    Dubal DB; Mueller S; Ruben BS; Engstrom JW; Josephson SA
    Muscle Nerve; 2009 Jun; 39(6):849-50. PubMed ID: 19358236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis.
    Hobson-Webb LD; Hehir M; Crum B; Visser A; Sanders D; Burns TM
    Muscle Nerve; 2015 Aug; 52(2):211-5. PubMed ID: 25906756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent.
    Esmaili N; Chams-Davatchi C; Valikhani M; Farshidfar F; Parvaneh N; Tamizifar B
    Eur J Dermatol; 2008; 18(2):159-64. PubMed ID: 18424375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil in myasthenia gravis: the unanswered question.
    Phan C; Sanders DB; Siddiqi ZA
    Expert Opin Pharmacother; 2008 Oct; 9(14):2545-51. PubMed ID: 18778192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depressive disorder associated with mycophenolate mofetil.
    Draper HM
    Pharmacotherapy; 2008 Jan; 28(1):136-9. PubMed ID: 18154484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.